Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis
June 18, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference
May 24, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates
May 11, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis; topline data from Saturn-1 expected this July Announced FDA...
Tarsus Pharmaceuticals, Inc. Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
May 06, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis may affect up to 25 million Americans and result in significant clinical, functional and psychosocial burden for patients Saturn-2 trial design similar to Saturn-1, first pivotal...
Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention
May 04, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention Allows initiation of Phase 1 study to evaluate safety, pharmacokinetics, and dosing More...
Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis
May 03, 2021 16:08 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans Atlas study shows that Demodex blepharitis negatively impacts daily life for 80 percent of patients ...
Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference
April 27, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
March 31, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021 Strategic partnership with LianBio in March 2021 for...
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease
March 29, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., SHANGHAI, China and PRINCETON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and LianBio, a...
Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel
January 19, 2021 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...